NCT00797303

The Effect of Bevacizumab on Corneal Neovascularization

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Instituto de Olhos de Goiania · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Detailed description

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization. Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Conditions

• Corneal Neovascularization

Interventions

Type	Name	Description
DRUG	Bevacizumab	subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-07-01
• Completion: 2008-11-01
• First posted: 2008-11-25
• Last updated: 2011-12-02